Pfizer Inc. (PFE)
After hours:
- Business Wire
Pfizer Granted FDA Fast Track Designation for Ervogastat/Clesacostat Combination for the Treatment of Non-Alcoholic Steatohepatitis (NASH)
NEW YORK, May 26, 2022--Pfizer Inc. (NYSE: PFE) today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Pfizer’s investigational combination therapy for the treatment of non-alcoholic steatohepatitis (NASH) with liver fibrosis: ervogastat (PF-06865571, a diacylglycerol O-acyltransferase 2 inhibitor, or DGAT2i) and clesacostat (PF-05221304, an acetyl-CoA carboxylase inhibitor, or ACCi). Fast Track is a process designed to facilitate the development and ex
- Motley Fool
Better Dividend Stock: Pfizer or Merck?
Pfizer (NYSE: PFE) and Merck (NYSE: MRK) have been giants in the pharmaceutical industry for years. The first metric that most investors look at when comparing dividend stocks is the dividend yield. Pfizer gets the nod with a dividend yield of 3.05%, a little higher than Merck's yield of 2.95%.
- Motley Fool
How Vaccine Cash Could Fuel Pfizer's Future Growth
Thanks to the success of its COVID-19 vaccine, Pfizer (NYSE: PFE) more than doubled its cash hoard in 2021. Here's how the company's big plan might play out. Pfizer set forth an ambitious goal to use its war chest to add $25 billion of revenue by 2030 through mergers and acquisitions, and it's been actively building its pipeline to reach that goal over the last several months.
